Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: J Vasc Interv Radiol. 2021 Jun 11;32(9):1296–1309.e7. doi: 10.1016/j.jvir.2021.06.001

APPENDIX F.

ILIOFEMORAL DVT SUBGROUP: CONTINUOUS TRIAL OUTCOMES, ANGIOJET-PCDT (ANY METHOD) VERSUS CONTROL

Outcome Control* (n = 100)
PCDT (n = 95)
PCDT: control difference
n Mean (SE) n Mean (SE) Mean difference (SE) P value
Villalta scale score
 At 6 mo 74 4.89 (0.54) 72 4.06 (0.53) −0.84 (0.55) .13
 At 12 mo 68 4.90 (0.52) 63 3.96 (0.51) −0.94 (0.50) .06
 At 18 mo 63 4.91 (0.55) 56 3.86 (0.54) −1.05 (0.57) .06
 At 24 mo 66 4.92 (0.63) 48 3.76 (0.61) −1.16 (0.71) .10
VCSS score
 At 6 mo 86 3.03 (0.39) 62 2.54 (0.35) 0.49 (0.45) .27
 At 12 mo 74 3.00 (0.39) 52 2.49 (0.36) 0.51 (0.46) .27
 At 18 mo 66 3.34 (0.40) 45 2.61 (0.38) 0.73 (0.48) .13
 At 24 mo 63 2.78 (0.40) 43 2.50 (0.39) 0.27 (0.49) .57
VEINES-QOL
 At 1 mo 86 7.00 (2.46) 73 19.64 (2.36) 12.64 (3.20) .0001
 At 6 mo 74 20.58 (2.67) 63 26.75 (2.5) 6.17 (3.42) .07
 At 12 mo 66 26.48 (2.66) 55 28.23 (2.49) 1.75 (3.34) .60
 At 18 mo 63 26.16 (2.61) 48 29.3 (2.46) 3.14 (3.19) .33
 At 24 mo 66 25.85 (2.87) 47 30.37 (2.74) 4.52 (3.53) .20
VEINES symptoms
 At 1 mo 86 5.87 (2.47) 73 17.27 (2.37) 11.40 (3.13) .0003
 At 6 mo 74 15.63 (2.44) 63 20.06 (2.30) 4.43 (3.02) .14
 At 12 mo 66 16.61 (2.38) 55 20.72 (2.25) 4.12 (2.88) .15
 At 18 mo 63 17.58 (2.56) 48 21.39 (2.44) 3.81 (3.11) .22
 At 24 mo 66 18.56 (2.93) 47 22.06 (2.81) 3.50 (3.64) .34

DVT = deep vein thrombosis; PCDT = pharmacomechanical catheter-directed venous thrombolysis; QOL = quality of life; SE = standard error; VCSS = venous clinical severity scale; VEINES = Venous Insufficiency Epidemiologic and Economic Study; VEINES-QOL = Venous Insufficiency Epidemiologic and Economic Study-Quality of Life.

*

Treatment groups are per-protocol patients.